BIIB's rFIXFc meets Phase III endpoints

Biogen Idec Inc. (NASDAQ:BIIB) and partner Swedish Orphan Biovitrum AB (SSE:SOBI) said rFIXFc as prophylaxis met the primary efficacy and safety endpoints in the Phase III B-LONG trial to treat hemophilia

Read the full 317 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE